Tamoxifen Orifarm

What Is Tamoxifen Orifarm and What Is It Used For?

Quick Answer: Tamoxifen Orifarm contains tamoxifen, a selective estrogen receptor modulator (SERM) that blocks estrogen's action on breast tissue. It is primarily prescribed for the treatment of hormone receptor-positive (HR+) breast cancer, both in early-stage and advanced disease.

Tamoxifen is classified as an anti-estrogen medication, meaning it works by preventing the natural hormone estrogen from stimulating the growth of certain breast cancer cells. Many breast cancers depend on estrogen to grow; these are referred to as hormone receptor-positive (HR+ or ER+) cancers. By occupying the estrogen receptors on cancer cells, tamoxifen effectively starves the tumor of its growth signal, slowing or halting disease progression.

First introduced in the 1970s, tamoxifen remains one of the most important and widely prescribed cancer medications globally. It is listed on the World Health Organization (WHO) Model List of Essential Medicines, reflecting its critical role in oncology. Over four decades of clinical research, including landmark trials such as the EBCTCG meta-analyses, have demonstrated that tamoxifen significantly reduces the risk of breast cancer recurrence and mortality.

Tamoxifen Orifarm is used in several clinical contexts. As adjuvant therapy, it is prescribed following surgery (with or without radiation and chemotherapy) to reduce the risk of cancer returning. In metastatic disease, it can slow tumor growth in patients with advanced breast cancer. Additionally, tamoxifen may be used for risk reduction in women at high risk of developing breast cancer, although this indication should be carefully discussed with an oncologist weighing individual benefits and risks.

Unlike aromatase inhibitors (such as letrozole or anastrozole), which are primarily used in postmenopausal women, tamoxifen is effective in both premenopausal and postmenopausal women. This makes it an indispensable option for younger women who cannot take aromatase inhibitors. The medication is taken orally as a tablet and is generally well tolerated over the extended treatment periods required for optimal cancer outcomes.

What Should You Know Before Taking Tamoxifen Orifarm?

Quick Answer: You should not take Tamoxifen Orifarm if you are allergic to tamoxifen or any of its ingredients, if you are pregnant, or if you are breastfeeding. Inform your doctor about all medications you take, especially antidepressants, as some can significantly reduce tamoxifen's effectiveness.

Contraindications

There are specific situations in which Tamoxifen Orifarm must not be used. Understanding these contraindications is essential for patient safety. Your prescribing physician will assess these factors before initiating treatment, but it is important that you are also aware of them.

Warnings and Precautions

Before and during treatment with Tamoxifen Orifarm, you should be aware of the following important safety considerations. Talk to your doctor, pharmacist, or nurse before starting this medication if any of these apply to you.

Gynecological monitoring: If you experience any unusual vaginal bleeding, pelvic pain, or pelvic pressure while taking or after taking Tamoxifen Orifarm, contact your doctor immediately. Tamoxifen can cause changes to the uterine lining (endometrium), and some of these changes may be serious, including endometrial cancer. Regular gynecological examinations are recommended during treatment.

Initial disease flare: At the beginning of treatment, some disease symptoms may temporarily worsen. Tumor-related pain may increase, and the affected tissue may appear to enlarge. If you also experience severe nausea and vomiting, contact your doctor promptly, as this could indicate changes in blood calcium levels (hypercalcemia) that require blood tests and monitoring.

Hereditary angioedema: If you have a history of hereditary angioedema, tamoxifen may trigger or worsen symptoms. Seek immediate medical attention if you develop swelling of the face, lips, tongue, or throat with difficulty swallowing or breathing.

Severe skin reactions: Serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with tamoxifen. Stop taking the medication and seek emergency medical care if you develop a rash with reddish, non-raised, target-like spots or round marks on the trunk, with blistering, mouth sores, or skin peeling.

Menstrual irregularities: In premenopausal women, menstruation may become irregular or stop entirely during treatment. This does not necessarily indicate menopause, and fertility may be preserved despite amenorrhea.

Thromboembolic risk: Tamoxifen increases the risk of blood clots (deep vein thrombosis, pulmonary embolism). This risk is particularly elevated in patients undergoing delayed breast reconstruction surgery using tissue flaps. If you are hospitalized for any reason, inform your healthcare team that you are taking tamoxifen.

Pregnancy and Breastfeeding

Tamoxifen Orifarm must not be used during pregnancy. There is evidence that tamoxifen may cause fetal harm. Before starting treatment, pregnancy must be excluded through appropriate testing. You must not become pregnant while taking tamoxifen or for at least 2 months after stopping the medication.

Importantly, hormonal contraceptives (birth control pills) should not be used for pregnancy prevention during tamoxifen therapy, as they may interfere with the medication's mechanism of action. Instead, barrier methods of contraception (such as condoms or a diaphragm) should be used.

Tamoxifen must not be used while breastfeeding. It is not known whether tamoxifen or its metabolites are excreted in human breast milk, and potential adverse effects on the nursing infant cannot be excluded.

Driving and Operating Machinery

Tamoxifen Orifarm is not expected to significantly impair your ability to drive or operate machinery. However, fatigue has been reported as a side effect. If you experience tiredness, dizziness, or visual disturbances, exercise caution when driving or operating machinery until these symptoms resolve. You are personally responsible for assessing whether you are fit to perform these activities.

How Does Tamoxifen Orifarm Interact with Other Drugs?

Quick Answer: Tamoxifen has clinically significant interactions with several medications. CYP2D6 inhibitors such as paroxetine, fluoxetine, and bupropion can dramatically reduce tamoxifen's effectiveness and should be avoided. Warfarin, phenytoin, and certain chemotherapy agents may also require dose adjustments when used concurrently.

Tamoxifen is metabolized in the liver, primarily by the cytochrome P450 enzyme CYP2D6, which converts it to its active metabolite endoxifen. This metabolite is responsible for much of tamoxifen's anti-cancer activity. Medications that inhibit CYP2D6 can substantially reduce endoxifen levels, potentially compromising treatment effectiveness. This pharmacokinetic interaction has been extensively studied and is considered clinically significant.

Major Interactions — Avoid Concurrent Use

The following medications are strong CYP2D6 inhibitors and should be avoided during tamoxifen therapy. Concurrent use can significantly reduce the plasma concentrations of endoxifen, the active metabolite of tamoxifen, potentially undermining the therapeutic benefit of cancer treatment.

Interactions Requiring Dose Adjustment

The following medications may interact with tamoxifen and require your doctor to adjust the dose of either tamoxifen or the interacting drug. These interactions do not necessarily require stopping either medication, but careful monitoring is essential.

What Is the Correct Dosage of Tamoxifen Orifarm?

Quick Answer: The recommended daily dose of Tamoxifen Orifarm is 20 mg, taken once daily or divided into two doses of 10 mg. Treatment duration for adjuvant breast cancer therapy is typically 5 years, though some patients may benefit from extended therapy up to 10 years.

Always take Tamoxifen Orifarm exactly as your doctor or pharmacist has instructed. Do not change the dose or stop treatment without consulting your healthcare provider. The tablet can be divided into two equal halves if needed. Take the medication at the same time each day to maintain consistent blood levels.

Adults

Children and Adolescents

Tamoxifen Orifarm is not routinely used in children and adolescents. Its use in pediatric populations is limited to rare, specialist-directed scenarios and is not covered by standard dosing guidelines. If tamoxifen is prescribed for a child or adolescent, the treating specialist will determine the appropriate dose.

Elderly Patients

No dose adjustment is required for elderly patients. Tamoxifen has been extensively studied in postmenopausal women and the standard 20 mg daily dose applies. However, elderly patients may have an increased risk of thromboembolic events, and this should be discussed with the prescribing physician.

Missed Dose

If you forget to take a dose of Tamoxifen Orifarm, take it as soon as you remember, provided it is not close to the time for your next dose. If it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one. Missing a single dose occasionally is unlikely to affect your overall treatment, but try to take your medication consistently.

Overdose

In the event of an overdose, anti-estrogenic effects may be expected. There is no specific antidote for tamoxifen overdose. If you have taken too much Tamoxifen Orifarm, or if a child has accidentally ingested the medication, contact your doctor, hospital, or poison control center immediately for risk assessment and guidance. Treatment is supportive and symptomatic.

What Are the Side Effects of Tamoxifen Orifarm?

Quick Answer: Like all medications, tamoxifen can cause side effects. The most common include hot flashes, fluid retention, vaginal discharge, nausea, and fatigue. Serious but rare side effects include blood clots (thromboembolism), endometrial cancer, and severe skin reactions. Most side effects are manageable, and the benefits of treatment generally outweigh the risks for patients with hormone receptor-positive breast cancer.

Not everyone who takes tamoxifen will experience side effects. Many side effects are mild and may decrease over time as your body adjusts to the medication. However, some side effects are serious and require immediate medical attention. Understanding the frequency and nature of potential adverse reactions helps you and your healthcare team monitor your health effectively during treatment.

How Should You Store Tamoxifen Orifarm?

Quick Answer: Store Tamoxifen Orifarm in its original packaging, protected from light. Keep it out of the sight and reach of children. Do not use after the expiry date printed on the packaging.

Proper storage of medications is essential to maintain their effectiveness and safety. Tamoxifen Orifarm should be stored under the following conditions:

• Keep out of sight and reach of children at all times to prevent accidental ingestion.
• Store in the original packaging to protect the tablets from light, as tamoxifen is light-sensitive.
• Do not use after the expiry date (marked as “EXP” on the packaging). The expiry date refers to the last day of that month.
• No special temperature requirements — store at room temperature below 25°C (77°F).

Do not dispose of medications in wastewater or household waste. Return unused or expired medication to your pharmacy for safe disposal. Proper disposal of pharmaceutical waste helps protect the environment.

What Does Tamoxifen Orifarm Contain?

Quick Answer: Each Tamoxifen Orifarm tablet contains tamoxifen citrate equivalent to 20 mg of tamoxifen as the active ingredient. Excipients include lactose monohydrate, magnesium stearate, sodium starch glycolate, povidone, microcrystalline cellulose, and potato starch.

Active Ingredient

The active substance is tamoxifen citrate, dosed to provide the equivalent of 20 mg tamoxifen per tablet. Tamoxifen citrate is the salt form used for pharmaceutical formulation, which provides good oral bioavailability and stability.

Inactive Ingredients (Excipients)

• Lactose monohydrate
• Magnesium stearate
• Sodium starch glycolate
• Povidone
• Microcrystalline cellulose
• Potato starch

Appearance and Pack Sizes

Tamoxifen Orifarm tablets are white or greyish-white, round, flat tablets with beveled edges, embossed with “ZT 20” on one side and a score line on the other side. The diameter is 10 mm. The tablet can be divided into two equal halves along the score line.

Available pack sizes: 14, 20, 21, 28, 30, 35, 40, 42, 50, 56, 60, 63, 91, 98, 100, 105, or 110 tablets. Not all pack sizes may be marketed in every country.

Marketing Authorization Holder and Manufacturer

Orifarm Generics A/S
Energivej 15, 5260 Odense S, Denmark

References and Medical Sources

This article is based on the following peer-reviewed sources, international guidelines, and regulatory documents:

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). “Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.” The Lancet, 2011; 378(9793): 771–784. DOI: 10.1016/S0140-6736(11)60993-8
2. Davies C, et al. “Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.” The Lancet, 2013; 381(9869): 805–816.
3. Gray RG, et al. “aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.” Journal of Clinical Oncology, 2013; 31(suppl): abstr 5.
4. World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List (2023). Geneva: World Health Organization.
5. European Medicines Agency (EMA). Summary of Product Characteristics: Tamoxifen. Accessed February 2026.
6. National Institute for Health and Care Excellence (NICE). “Early and locally advanced breast cancer: diagnosis and management.” NICE Guideline NG101, updated 2023.
7. U.S. Food and Drug Administration (FDA). Tamoxifen Citrate Prescribing Information. Revised 2024.
8. Borges S, et al. “Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism.” Clinical Pharmacology & Therapeutics, 2006; 80(1): 61–74.
9. Jordan VC. “Tamoxifen: a most unlikely pioneering medicine.” Nature Reviews Drug Discovery, 2003; 2(3): 205–213.
10. British National Formulary (BNF). “Tamoxifen.” NICE Evidence Services, accessed February 2026.

Editorial Team

This article was written and reviewed by the iMedic Medical Editorial Team, which includes specialists in oncology, clinical pharmacology, and evidence-based medicine. All content follows the GRADE evidence framework and adheres to international guidelines from the WHO, EMA, FDA, and NICE.

Evidence Standard: Level 1A — Based on systematic reviews of randomized controlled trials and international clinical guidelines. No commercial funding or pharmaceutical industry influence.